NHS Approves First-Line Immunotherapy-Chemotherapy Combination for Advanced Endometrial Cancer
London, UK – August 7, 2025In a significant advancement for cancer treatment, the NHS has approved a new combination therapy for patients with primary advanced or recurrent endometrial cancer. This marks the first time immunotherapy has been integrated with chemotherapy as a first-line option for this patient group. The approved regimen combines pembrolizumab (Keytruda), an […]
Continue Reading